Article info
PDFHow to do it
Azathioprine and the neurologist
- Correspondence to Dr Usman Khan, Neurology, St George's University Hospital, London SW17 0QT, UK; usman.khan4{at}nhs.net
Citation
Azathioprine and the neurologist
Publication history
- Accepted July 8, 2019
- First published August 23, 2019.
Online issue publication
January 14, 2020
Article Versions
- Previous version (23 August 2019).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.
Other content recommended for you
- TPMT testing before azathioprine therapy?
- Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease
- A practical guide to thiopurine prescribing and monitoring in IBD
- Optimising use of thiopurines in inflammatory bowel disease
- TPMT in the treatment of Crohn's disease with azathioprine
- Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease
- Azathioprine-induced pancytopenia with normal TPMT activity presenting with HSV oral ulcers
- Thiopurine S-methyltransferase (TPMT) assessment prior to starting thiopurine drug treatment; a pharmacogenomic test whose time has come
- Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease
- Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease